Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma : A case report
Articolo
Data di Pubblicazione:
2021
Citazione:
Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma : A case report / G. Bonfante, E. Fantinel, C. Masini, F. Bergamaschi, S. Micali, B. Rocco. - In: UROLOGY CASE REPORTS. - ISSN 2214-4420. - 34(2021), pp. 101444.1-101444.3. [10.1016/j.eucr.2020.101444]
Abstract:
Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Breast metastasis; Immune checkpoint inhibitor; Metastatic urothelial carcinoma; PD-1; Radiotherapy
Elenco autori:
G. Bonfante, E. Fantinel, C. Masini, F. Bergamaschi, S. Micali, B. Rocco
Link alla scheda completa: